CDNA microarrays hold great promise for characterizing disease and performing genetic studies, but they're not exactly an out-of-the-box technology just yet. Often the scientists must prepare their own chips. Yet, this process is limited by the amount of space on the array itself—forcing researchers to make choices about which genes to include in their sample. Clinical microarray applications are further limited by the availability of sufficient cell numbers for testing purposes.

Illuminating Pathology: Researchers are using the power of microarrays to advance clinical medicine.

In 2000, two groups of researchers took a step towards establishing the clinical efficacy of gene expression profiling when they correlated that data with a clinical outcome in diffuse large B-cell lymphoma (DLBCL) and a phenotype in cutaneous malignant melanoma. For their analysis of melanoma samples, Jeffrey Trent, director of intramural research at the National Institutes of Health's National Human Genome Research Institute, and colleagues...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?